featured
Toxicity and Clinical Outcomes in Full vs Reduced Starting-Dose Cabozantinib in Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Genitourinary Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients
Clin Genitourin Cancer 2021 Nov 12;[EPub Ahead of Print], DJ Martini, ST Evans, Y Liu, JM Shabto, OE Uner, TA Olsen, JT Brown, GA Russler, L Yantorni, S Caulfield, JM Goldman, B Nazha, WB Harris, VA Master, O Kucuk, BC Carthon, MA BilenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.